Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SOBI Acquires European Rights to Dongbao Anemia Drug

publication date: Nov 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Swedish Orphan Biovitrum has in-licensed European marketing rights to Iron Sucrose Rechon, an anemia drug, from Dongbao Group’s subsidiary, Rechon Life Science Group, a contract manufacturer located in Malmo, Sweden. Sobi will pay a $1.7 million regulatory milestone to Rechon, plus a transfer price and a royalty on net sales. More details....

Stock Symbols: (STO: SOBI) (SHEX: 600867)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...